Carrelizumab combined with XELOX in the treatment of stage IIIB/IIIC gastric cancer and gastroesophageal junction adenocarcinoma after D2 radical resection: a phase II clinical single-center, exploratory study

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2021
This article has no abstract
Epistemonikos ID: c2238d301d381e865c87a42caad468f8267e0643
First added on: Apr 08, 2025